HAEMONETICS CORP

Listed Company

HAECIK 0000313143NYSELarge AcceleratedSurgical & Medical Instruments & ApparatusMassachusettsFY ends Mar 28

Period

FY 2026

Revenue

—

Net Income

$97.31M

Total Assets

$2.40B

Equity

$796.32M

Shares Out

45.45M

Op. Cash Flow

$293.22M

HAE$77.90+5.84% · past yearDBEQ Basic

Daily closing prices

Business

Haemonetics is a global medical technology company providing automated plasma collection systems, blood collection and processing devices, and hospital technologies for interventional and blood management procedures. The company offers plasma collection devices and donor management software to plasma collection centers, blood component collection systems to blood centers, and vascular closure, sensor-guided, esophageal protection, hemostasis management, cell salvage, and transfusion management products to hospitals. Haemonetics markets its products in approximately 90 countries through direct sales and independent distributors to biopharmaceutical companies, blood centers, hospitals, and group purchasing organizations.

Summary from 10-K filed 2026-05-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Net revenues	1,334	1,361	1,309	1,169	993
Cost of goods sold	546	612	618	554	488
Gross profit	788	749	692	615	506
Research and development	60	63	54	50	47
Selling, general and administrative	442	437	430	377	340
Amortization of acquired intangible assets	44	48	32	33	47
Remeasurement of contingent consideration	−2	−23	0	0	—
Impairment of intangible assets	87	2	10	—	—
Total operating expenses	631	527	527	459	425
Operating income	157	222	165	156	81
Interest and other expense, net	−29	−10	−13	−15	−17
Income before provision for income taxes	128	212	152	141	64
Provision for income taxes	31	44	34	26	20
Net income	97	168	118	115	43
Basic (in dollars per share)	2.06	3.33	2.32	2.27	0.85
Diluted (in dollars per share)	2.05	3.31	2.29	2.24	0.84
Basic (in shares)	47	50	51	51	51
Diluted (in shares)	47	51	51	51	51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Cash and cash equivalents	245	307	179	284	259
Accounts receivable, less allowance for credit losses of $3,693 as of March 28, 2026 and $6,300 as of March 29, 2025	217	203	207	179	159
Inventories, net	306	365	317	259	293
Prepaid expenses and other current assets	66	60	66	47	44
Total current assets	835	935	769	770	756
Property, plant and equipment, net	306	284	311	311	258
Intangible assets, less accumulated amortization of $363,763 as of March 28, 2026 and $316,313 as of March 29, 2025	448	456	406	276	310
Goodwill	656	604	565	466	467
Deferred tax asset	10	8	8	5	4
Other long-term assets	142	164	136	107	63
Total assets	2,396	2,451	2,196	1,935	1,860
Notes payable and current maturities of long-term debt	5	304	10	12	214
Accounts payable	51	67	73	64	58
Accrued payroll and related costs	68	59	81	64	49
Other current liabilities	158	148	136	112	121
Total current liabilities	283	578	300	252	442
Long-term debt, net of current maturities	1,220	921	798	754	559
Deferred tax liability	38	63	63	36	29
Other long-term liabilities	59	68	75	75	80
Common stock, $0.01 par value; Authorized 150,000,000 shares; Issued and outstanding 45,252,667 shares as of March 28, 2026 and 48,215,899 shares as of March 29, 2025	453,000	482,000	508,000	504,000	511,000
Additional paid-in capital	554	523	635	595	572
Retained earnings	279	352	360	253	202
Accumulated other comprehensive loss	−38	−55	−36	−30	−26
Total stockholders equity	796	821	960	818	749
Total liabilities and stockholders equity	2,396	2,451	2,196	1,935	1,860

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Depreciation and amortization	112	116	97	93	98
Amortization of fair value inventory step-up	6	15	3	0	0
Share-based compensation expense	34	30	28	26	24
Impairment of intangible assets	87	2	10	607,000	8
Gain on repurchase of convertible senior notes, net	0	−13	0	0	—
Gains on sales of property, plant and equipment	−714,000	−16	−1	−943,000	—
Remeasurement of contingent consideration	−2	−23	0	−504,000	—
Deferred income taxes	−26	−5	−11	5	5
Other non-cash operating activities	11	10	12	9	6
Change in accounts receivable	−15	7	−24	−24	−35
Change in inventories	47	−65	−60	31	24
Change in prepaid income taxes	−5	226,000	−983,000	2	3
Change in other assets and other liabilities	−35	−25	−34	−22	−15
Change in accounts payable and accrued expenses	−17	−19	45	40	8
Net cash provided by operating activities	293	182	182	273	172
Capital expenditures	−33	−39	−38	−191	−97
Proceeds from divestiture and sale of assets	0	43	2	850,000	11
Proceeds from sale of property, plant and equipment	1	23	2	2	2
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	−52	−21	−28	81	52
Acquisitions	60	151	244	3	3
Other investments	−36	−17	−16	−33	0
Net cash used in investing activities	−180	−162	−322	−144	−86
Proceeds from issuance of convertible notes	0	700	0	0	0
Repayment and repurchase of convertible notes	−300	−186	0	—	—
Purchase of capped call related to convertible notes	0	−88	0	0	0
Term loan borrowings	0	250	0	280	0
Term loan redemption	0	−263	0	−280	0
Repayment of term loan borrowings	−6	−5	−12	—	—
Proceeds from revolving facility	300	0	110	50	0
Payments on revolving facility	0	−50	−60	−50	0
Debt issuance costs	0	−23	0	−1	0
Proceeds from employee stock purchase plan	8	8	7	7	4
Cash used to net share settle employee equity awards	−5	−10	−6	0	0
Share repurchases	−175	−225	0	−75	0
Other financing activities	−102,000	−249,000	−922,000	−44,000	−5,000
Net cash (used in) provided by financing activities	−178	109	38	−100	−16
Effect of exchange rates on cash and cash equivalents	3	−685,000	−3	−4	−3
Net Change in Cash and Cash Equivalents	−61	128	−106	25	67
Interest paid	17	17	21	14	6
Income taxes paid	61	49	53	18	24
Fair value of previously held equity interest settled in connection with acquisition	47	0	0	—	—
Settlement of pre-existing loan in connection with acquisition	36	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is HAEMONETICS CORP's CIK number?

HAEMONETICS CORP's SEC CIK number is 0000313143 (313143). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find HAEMONETICS CORP's SEC filings?

All of HAEMONETICS CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did HAEMONETICS CORP last report earnings?

HAEMONETICS CORP (HAE) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000313143-26-000031). This is HAEMONETICS CORP's most recent earnings filing of record — not a forecast of its next earnings date.

What is HAEMONETICS CORP's most recent earnings 8-K?

HAEMONETICS CORP's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0000313143-26-000031. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View HAEMONETICS CORP's latest earnings 8-K →
Look up any company's CIK number →